Table S6.
Mean change of visual acuity and central macular thickness after receiving ranibizumab and bevacizumab for the treatment of age-related macular degeneration
| Author | Year | IVR | IVB | ||||
|---|---|---|---|---|---|---|---|
|
|
|
||||||
| n | Mean | SD | n | Mean | SD | ||
| VA (ETDRS letter score) | |||||||
| Martin et al25 | 2011 | 285 | 6.80 | 13.10 | 271 | 5.90 | 15.70 |
| Gharbiya et al24 | 2010 | 16 | 17.31 | 11.10 | 16 | 15.87 | 8.41 |
| Biswas et al23 | 2011 | 54 | 3.56 | 8.90 | 50 | 3.96 | 8.36 |
| Subramanian et al26 | 2010 | 7 | 6.29 | 13.74 | 15 | 7.53 | 15.32 |
| USMD (95% CI) | 0.49 (95% CI, −1.37 to 2.34) | ||||||
| CMT (μm) | |||||||
| Martin et al25 | 2011 | 285 | −168.0 | 186.00 | 271 | −152.00 | 178.00 |
| Biswas et al23 | 2011 | 54 | −44.7 | 66.56 | 50 | −37.96 | 55.33 |
| Subramanian et al26 | 2009 | 7 | −102.0 | 72.90 | 13 | −35.00 | 80.50 |
| USMD (95% CI) | −14.18 (95% CI, −32.06 to 3.70) | ||||||
Abbreviations: CI, confidence interval; CMT, central macular thickness; IVB, intravitreal bevacizumab; IVR, intravitreal ranibizumab; SD, standard deviation; USMD, unstandardized mean difference; VA, visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study.